Key result
Anthracycline-induced cardiomyopathy is driven by free radical release, DNA interaction, and apoptosis, with emerging therapeutic perspectives focusing on molecular mechanisms like Kinin B1 receptors and erythropoietin.
Understanding the molecular mechanisms of anthracycline-induced cardiomyopathy highlights potential new therapeutic targets like KB1R antagonists and erythropoietin.
Highlights potential KB1R and erythropoietin targets in anthracycline cardiomyopathy; leaves open clinical validation in prospective trials.
Anthracyclines are among the most powerful drugs for the treatment of oncologic diseases both in childhood and in adulthood. Nevertheless, their major antineoplastic efficacy can be seriously impaired by collateral toxic cardiac effects causing cardiomyopathy with chronic heart failure that is refractory to conventional medical therapy.This article reports possible subcellular molecular alterations of anthracycline-induced cardiomyopathy (reactive oxygen species formation, apoptosis, inflammatory signalling, altered expression of cardiomyocytes specific genes, etc) and indicates some new therapeutic perspectives resulting from a better understanding of the molecular pathogenetic mechanisms.
No takes yet. Share an insight, caveat, or question.
Giuseppe Distefano (2009) conducted a review in Anthracycline-induced cardiomyopathy. Anthracyclines was evaluated. Anthracycline-induced cardiomyopathy is driven by free radical release, DNA interaction, and apoptosis, with emerging therapeutic perspectives focusing on molecular mechanisms like Kinin B1 receptors and erythropoietin.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: